Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MK-5890 |
Trade Name | |
Synonyms | |
Drug Descriptions |
MK-5890 is monoclonal antibody that targets CD27, potentially resulting in increased T-cell dependent immune responses, and antitumor activity (Journal for ImmunoTherapy of Cancer 2020;8). |
DrugClasses | CD27 Antibody 3 |
CAS Registry Number | NA |
NCIT ID | C172056 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + Etoposide + MK-5890 + Pembrolizumab | Carboplatin Etoposide MK-5890 Pembrolizumab | 0 | 1 |
Cisplatin + Etoposide + MK-5890 + Pembrolizumab | Cisplatin Etoposide MK-5890 Pembrolizumab | 0 | 1 |
MK-5890 | MK-5890 | 0 | 1 |
MK-5890 + Pembrolizumab | MK-5890 Pembrolizumab | 0 | 2 |